Moneycontrol
Get App
Last Updated : Aug 24, 2016 12:47 PM IST | Source: CNBC-TV18

Aurobindo to see growth in H2; capacity constraints continue: PL

While the numbers have been in-line, the company has headroom for better growth, says Surajit Pal, Pharma analyst at Prabhudas Lilladher. Capacity constraints for approved products continue to weigh on Aurobindo.


Aurobindo Pharma reported in-line numbers with 23.81 percent jump in consolidated net profit to Rs 584.96 crore in the first quarter ended June 30. Total income from operation too went up to Rs 3,725.90 crore as against Rs 3,298.93 crore in the same period year ago.

While the numbers have been in-line, the company has headroom for better growth, says Surajit Pal, Pharma analyst at Prabhudas Lilladher. Capacity constraints for approved products continue to weigh on Aurobindo.

Growth in topline and bottomline reflects improvement in the Europe markets, Pal says adding that the company has potential to maintain 10 percent plus growth for next 2-3 years.

Pal believes major growth for Aurobindo will come in second half of FY17.

Watch video for more..

Subscribe to Moneycontrol Pro's Annual plan for Rs 399/- for the first year. Use coupon PRO2020 (Available on Web & Android only).

First Published on Aug 24, 2016 12:39 pm
Sections
Follow us on